EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
暂无分享,去创建一个
G. Baron | P. Ravaud | X. Mariette | E. Theander | J. Gottenberg | H. Bootsma | R. Seror | C. Vitali | S. Bowman | A. Tzioufas | S. Bowman
[1] A. Vissink,et al. Rituximab treatment in primary Sjogren's syndrome : A double-blind placebo controlled trial , 2008 .
[2] J. Krischer,et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis , 2008, Annals of the rheumatic diseases.
[3] P. Merkel,et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. , 2008, Arthritis and rheumatism.
[4] P. Emery,et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study , 2008, Annals of the rheumatic diseases.
[5] D A Isenberg,et al. Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. , 2007, Rheumatology.
[6] S. Bombardieri,et al. Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. , 2007, Arthritis and rheumatism.
[7] B. Cochener,et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). , 2007, Arthritis and rheumatism.
[8] X. Mariette,et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.
[9] L. Jacobsson,et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors , 2005, Annals of the rheumatic diseases.
[10] A. Vissink,et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.
[11] X. Mariette,et al. Correlation of serum B lymphocyte stimulator and β2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome , 2005, Annals of the rheumatic diseases.
[12] A. Vissink,et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma , 2004, Annals of the rheumatic diseases.
[13] S. Pillemer,et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. , 2004, Arthritis and rheumatism.
[14] G. Baron,et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.
[15] Edward C. Jones,et al. A comparison of two time intervals for test-retest reliability of health status instruments. , 2003, Journal of clinical epidemiology.
[16] R. Jonsson,et al. Revisiting Sjögren's syndrome in the new millennium: perspectives on assessment and outcome measures. Report of a workshop held on 23 March 2000 at Oxford, UK. , 2001, Rheumatology.
[17] S. Bowman,et al. Outcome measures in Sjögren's syndrome. , 2001, Rheumatology.
[18] D. Altman,et al. Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.
[19] F. Vivino,et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. , 1999, Archives of internal medicine.
[20] P. Venables,et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. , 1998, The Journal of rheumatology.
[21] A. Tzioufas,et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. , 1996, Arthritis and rheumatism.
[22] E. Schned,et al. Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.
[23] A. van der Heide,et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. , 1993, Annals of the rheumatic diseases.
[24] van der Heijde Dm,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .
[25] D. Sackett,et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.
[26] D. Symmons,et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). , 1988, The Quarterly journal of medicine.
[27] D. Symmons,et al. Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus , 1988 .
[28] V. Yohai. HIGH BREAKDOWN-POINT AND HIGH EFFICIENCY ROBUST ESTIMATES FOR REGRESSION , 1987 .
[29] C. Papadimitriou,et al. Cyclosporin A (CyA) in primary Sjögren's syndrome: a double blind study. , 1986, Annals of the rheumatic diseases.
[30] P. Rousseeuw. Least Median of Squares Regression , 1984 .
[31] A. Claudy,et al. Disease activity in systemic lupus erythematosus , 1979, Clinical and experimental dermatology.
[32] Jacob Cohen,et al. Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit. , 1968 .
[33] Jacob Cohen. A Coefficient of Agreement for Nominal Scales , 1960 .
[34] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[35] S. Pillemer,et al. Outcome measures for Sjögren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. , 2005, The Journal of rheumatology.
[36] A. Vissink,et al. Rituximab treatment in primary Sjogren's syndrome , 2005 .
[37] M. A. van 't Hof,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.